TrialThe oncologist2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Matthew P Goetz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this paperpooled ittrialcites it